Roche Reports Results of Faricimab in Four P-III Studies for Diabetic Macular Edema and Age-Related Macular Degeneration

February 12, 2021 Auto Bot Age Related Macular Degeneration, Clinical Trials, Diabetic Macular Edema, Global, reports, results, Roche 0

Shots:

  • The P-III YOSEMITE & RHINE studies involve assessing faricimab (6mg at personalized dosing intervals of up to 4mos. and at fixed 2mos. intervals) vs aflibercept (2mg, fixed 2mos. intervals) in 1891 patients with DME
  • The P-III TENAYA & LUCERNE studies assessing faricimab (6mg administered at fixed intervals of every 2,3 & 4mos. based on objective assessment of disease activity @20 & 24wks.) vs aflibercept in 1329 patients with nAMD
  • The studies showed, i.e faricimab demonstrated non-inferior visual acuity gains and shows greater reductions in CST, thus reducing the treatment burden for patients and was well tolerated with no new safety signals identified

Click here ­to­ read full press release/ article | Ref: Roche | Image: Pharmaceutical Technology

The post Roche Reports Results of Faricimab in Four P-III Studies for Diabetic Macular Edema and Age-Related Macular Degeneration first appeared on PharmaShots.